{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T01:18:24Z","timestamp":1778721504108,"version":"3.51.4"},"reference-count":46,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,5,1]],"date-time":"2020-05-01T00:00:00Z","timestamp":1588291200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,5,1]],"date-time":"2020-05-01T00:00:00Z","timestamp":1588291200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,4,3]],"date-time":"2021-04-03T00:00:00Z","timestamp":1617408000000},"content-version":"am","delay-in-days":337,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Nuclear Medicine and Biology"],"published-print":{"date-parts":[[2020,5]]},"DOI":"10.1016\/j.nucmedbio.2020.03.005","type":"journal-article","created":{"date-parts":[[2020,3,30]],"date-time":"2020-03-30T11:01:56Z","timestamp":1585566116000},"page":"88-95","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":13,"special_numbering":"C","title":["A comparative study of peptide-based imaging agents [68Ga]Ga-PSMA-11, [68Ga]Ga-AMBA, [68Ga]Ga-NODAGA-RGD and [68Ga]Ga-DOTA-NT-20.3 in preclinical prostate tumour models"],"prefix":"10.1016","volume":"84-85","author":[{"given":"Jules","family":"Zhang-Yin","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Claire","family":"Provost","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G\u00e9raldine","family":"Cancel-Tassin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Timofei","family":"Rusu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mallaurie","family":"Penent","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Camelia","family":"Radulescu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eva","family":"Comperat","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Olivier","family":"Cussenot","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fran\u00e7oise","family":"Montravers","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rapha\u00eble","family":"Renard-Penna","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jean-No\u00ebl","family":"Talbot","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aur\u00e9lie","family":"Prignon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.nucmedbio.2020.03.005_bb0005","doi-asserted-by":"crossref","first-page":"792","DOI":"10.5812\/numonthly.9430","article-title":"Molecular pathways in prostate cancer","volume":"5","author":"Mazaris","year":"2013","journal-title":"Nephro-Urology Monthly"},{"key":"10.1016\/j.nucmedbio.2020.03.005_bb0010","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1016\/S0022-5347(05)63946-8","article-title":"Biochemical (prostate specific antigen) recurrence probability following radical prostatectomy for clinically localized prostate cancer","volume":"169","author":"Han","year":"2003","journal-title":"J Urol"},{"key":"10.1016\/j.nucmedbio.2020.03.005_bb0015","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/j.crad.2007.05.022","article-title":"The diagnostic accuracy of CT and MRI in the staging of pelvic lymph nodes in patients with prostate cancer: a meta-analysis","volume":"63","author":"Hovels","year":"2008","journal-title":"Clin Radiol"},{"key":"10.1016\/j.nucmedbio.2020.03.005_bb0020","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1016\/S0022-5347(05)64906-3","article-title":"Comparison of [18F]fluorocholine and [18F]fluorodeoxyglucose for positron emission tomography of androgen dependent and androgen independent prostate cancer","volume":"168","author":"Price","year":"2002","journal-title":"J Urol"},{"key":"10.1016\/j.nucmedbio.2020.03.005_bb0025","series-title":"Radiographics: a review publication of the Radiological Society of North America, Inc","first-page":"142","article-title":"Molecular imaging of prostate cancer","volume":"36","author":"Wibmer","year":"2016"},{"key":"10.1016\/j.nucmedbio.2020.03.005_bb0030","doi-asserted-by":"crossref","first-page":"1720","DOI":"10.2967\/jnumed.116.172627","article-title":"68Ga-PSMA PET\/CT detects the location and extent of primary prostate cancer","volume":"57","author":"Fendler","year":"2016","journal-title":"J Nucl Med"},{"key":"10.1016\/j.nucmedbio.2020.03.005_bb0035","doi-asserted-by":"crossref","first-page":"668","DOI":"10.2967\/jnumed.115.154153","article-title":"Evaluation of hybrid (6)(8)Ga-PSMA ligand PET\/CT in 248 patients with biochemical recurrence after radical prostatectomy","volume":"56","author":"Eiber","year":"2015","journal-title":"J Nucl Med"},{"key":"10.1016\/j.nucmedbio.2020.03.005_bb0040","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1016\/j.eururo.2016.06.021","article-title":"Sensitivity, specificity, and predictors of positive (68)Ga-prostate-specific membrane antigen positron emission tomography in advanced prostate Cancer: a systematic review and meta-analysis","volume":"70","author":"Perera","year":"2016","journal-title":"Eur Urol"},{"key":"10.1016\/j.nucmedbio.2020.03.005_bb0045","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1002\/pros.20910","article-title":"Shared TP53 gene mutation in morphologically and phenotypically distinct concurrent primary small cell neuroendocrine carcinoma and adenocarcinoma of the prostate","volume":"69","author":"Hansel","year":"2009","journal-title":"Prostate"},{"key":"10.1016\/j.nucmedbio.2020.03.005_bb0050","doi-asserted-by":"crossref","first-page":"e65","DOI":"10.1016\/j.clgc.2016.09.002","article-title":"Correlation of PSMA-targeted (18)F-DCFPyL PET\/CT findings with immunohistochemical and genomic data in a patient with metastatic neuroendocrine prostate cancer","volume":"15","author":"Tosoian","year":"2017","journal-title":"Clin Genitourin Cancer"},{"key":"10.1016\/j.nucmedbio.2020.03.005_bb0055","first-page":"1655","article-title":"Prostatic carcinoma cell migration via alpha(v)beta3 integrin is modulated by a focal adhesion kinase pathway","volume":"59","author":"Zheng","year":"1999","journal-title":"Cancer Res"},{"key":"10.1016\/j.nucmedbio.2020.03.005_bb0060","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1002\/pros.21434","article-title":"Profiling gastrin-releasing peptide receptor in prostate tissues: clinical implications and molecular correlates","volume":"72","author":"Beer","year":"2012","journal-title":"Prostate"},{"key":"10.1016\/j.nucmedbio.2020.03.005_bb0065","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1158\/0008-5472.CAN-09-1252","article-title":"Altered expression of neurotensin receptors is associated with the differentiation state of prostate cancer","volume":"70","author":"Swift","year":"2010","journal-title":"Cancer Res"},{"key":"10.1016\/j.nucmedbio.2020.03.005_bb0070","doi-asserted-by":"crossref","first-page":"9578","DOI":"10.1073\/pnas.1106383108","article-title":"Noninvasive measurement of androgen receptor signaling with a positron-emitting radiopharmaceutical that targets prostate-specific membrane antigen","volume":"108","author":"Evans","year":"2011","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.nucmedbio.2020.03.005_bb0075","first-page":"16","article-title":"Establishment and characterization of a human prostatic carcinoma cell line (PC-3)","volume":"17","author":"Kaighn","year":"1979","journal-title":"Invest Urol"},{"key":"10.1016\/j.nucmedbio.2020.03.005_bb0080","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1007\/s11626-999-0115-4","article-title":"A new human prostate carcinoma cell line, 22Rv1","volume":"35","author":"Sramkoski","year":"1999","journal-title":"In Vitro Cell Dev Biol Anim"},{"key":"10.1016\/j.nucmedbio.2020.03.005_bb0085","doi-asserted-by":"crossref","first-page":"2776","DOI":"10.1021\/acs.molpharmaceut.9b00283","article-title":"Preclinical evaluation of (68)Ga-DOTA-NT-20.3: a promising PET imaging probe to discriminate human pancreatic ductal adenocarcinoma from pancreatitis","volume":"16","author":"Prignon","year":"2019","journal-title":"Mol Pharm"},{"key":"10.1016\/j.nucmedbio.2020.03.005_bb0090","doi-asserted-by":"crossref","first-page":"19307","DOI":"10.18632\/oncotarget.25028","article-title":"Comparison and evaluation of two RGD peptides labelled with (68)Ga or (18)F for PET imaging of angiogenesis in animal models of human glioblastoma or lung carcinoma","volume":"9","author":"Provost","year":"2018","journal-title":"Oncotarget"},{"key":"10.1016\/j.nucmedbio.2020.03.005_bb0095","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/j.nucmedbio.2014.10.003","article-title":"(68)Ga-AMBA and (18)F-FDG for preclinical PET imaging of breast cancer: effect of tamoxifen treatment on tracer uptake by tumor","volume":"42","author":"Prignon","year":"2015","journal-title":"Nucl Med Biol"},{"key":"10.1016\/j.nucmedbio.2020.03.005_bb0100","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1186\/2191-219X-3-31","article-title":"Evaluation of androgen-induced effects on the uptake of [18F]FDG, [11C]choline and [11C]acetate in an androgen-sensitive and androgen-independent prostate cancer xenograft model","volume":"3","author":"Emonds","year":"2013","journal-title":"EJNMMI Res"},{"key":"10.1016\/j.nucmedbio.2020.03.005_bb0105","doi-asserted-by":"crossref","first-page":"1257","DOI":"10.1007\/s00259-011-1775-3","article-title":"Gastrin-releasing peptide receptor-based targeting using bombesin analogues is superior to metabolism-based targeting using choline for in vivo imaging of human prostate cancer xenografts","volume":"38","author":"Schroeder","year":"2011","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1016\/j.nucmedbio.2020.03.005_bb0110","doi-asserted-by":"crossref","first-page":"1654","DOI":"10.2967\/jnumed.110.086702","article-title":"Assessment of PET tracer uptake in hormone-independent and hormone-dependent xenograft prostate cancer mouse models","volume":"52","author":"Kukuk","year":"2011","journal-title":"J Nucl Med"},{"key":"10.1016\/j.nucmedbio.2020.03.005_bb0115","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.7150\/thno.12938","article-title":"Pilot prospective evaluation of (18)F-Alfatide II for detection of skeletal metastases","volume":"5","author":"Mi","year":"2015","journal-title":"Theranostics"},{"key":"10.1016\/j.nucmedbio.2020.03.005_bb0120","doi-asserted-by":"crossref","DOI":"10.3390\/cancers10020044","article-title":"Integrin inhibitors in prostate cancer","volume":"10","author":"Juan-Rivera","year":"2018","journal-title":"Cancers"},{"key":"10.1016\/j.nucmedbio.2020.03.005_bb0125","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1007\/s00726-010-0762-5","article-title":"A new 18F-labeled BBN-RGD peptide heterodimer with a symmetric linker for prostate cancer imaging","volume":"41","author":"Yan","year":"2011","journal-title":"Amino Acids"},{"key":"10.1016\/j.nucmedbio.2020.03.005_bb0130","doi-asserted-by":"crossref","first-page":"1595","DOI":"10.1021\/acs.bioconjchem.8b00113","article-title":"Novel (64)Cu labeled RGD2-BBN heterotrimers for PET imaging of prostate cancer","volume":"29","author":"Lucente","year":"2018","journal-title":"Bioconjug Chem"},{"key":"10.1016\/j.nucmedbio.2020.03.005_bb0135","doi-asserted-by":"crossref","first-page":"228","DOI":"10.2967\/jnumed.116.177048","article-title":"Clinical translation of a dual integrin alphavbeta3- and gastrin-releasing peptide receptor-targeting PET radiotracer, 68Ga-BBN-RGD","volume":"58","author":"Zhang","year":"2017","journal-title":"J Nucl Med"},{"key":"10.1016\/j.nucmedbio.2020.03.005_bb0140","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1053\/j.semnuclmed.2016.07.006","article-title":"PSMA PET and radionuclide therapy in prostate cancer","volume":"46","author":"Bouchelouche","year":"2016","journal-title":"Semin Nucl Med"},{"key":"10.1016\/j.nucmedbio.2020.03.005_bb0145","doi-asserted-by":"crossref","DOI":"10.1155\/2018\/8046541","article-title":"Preparation of (68)Ga-PSMA-11 with a synthesis module for micro PET-CT imaging of PSMA expression during prostate cancer progression","volume":"2018","author":"Wang","year":"2018","journal-title":"Contrast Media Mol Imaging"},{"key":"10.1016\/j.nucmedbio.2020.03.005_bb0150","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1002\/pros.20413","article-title":"Comparative study of PSMA expression in the prostate of mouse, dog, monkey, and human","volume":"66","author":"Aggarwal","year":"2006","journal-title":"Prostate"},{"key":"10.1016\/j.nucmedbio.2020.03.005_bb0155","doi-asserted-by":"crossref","first-page":"e163","DOI":"10.1097\/RLU.0000000000000594","article-title":"Metastatic poorly differentiated prostatic carcinoma with neuroendocrine differentiation: negative on 68Ga-PSMA PET\/CT","volume":"40","author":"Chakraborty","year":"2015","journal-title":"Clin Nucl Med"},{"key":"10.1016\/j.nucmedbio.2020.03.005_bb0160","doi-asserted-by":"crossref","first-page":"867","DOI":"10.2967\/jnumed.112.114082","article-title":"Plasma pharmacokinetics, whole-body distribution, metabolism, and radiation dosimetry of 68Ga bombesin antagonist BAY 86-7548 in healthy men","volume":"54","author":"Roivainen","year":"2013","journal-title":"J Nucl Med"},{"key":"10.1016\/j.nucmedbio.2020.03.005_bb0165","doi-asserted-by":"crossref","first-page":"5434","DOI":"10.1158\/1078-0432.CCR-12-3490","article-title":"In vivo imaging of prostate cancer using [68Ga]-labeled bombesin analog BAY86-7548","volume":"19","author":"Kahkonen","year":"2013","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.nucmedbio.2020.03.005_bb0170","doi-asserted-by":"crossref","first-page":"412","DOI":"10.7150\/thno.7324","article-title":"Positron emission tomography (PET) imaging of prostate cancer with a gastrin releasing peptide receptor antagonist--from mice to men","volume":"4","author":"Wieser","year":"2014","journal-title":"Theranostics"},{"key":"10.1016\/j.nucmedbio.2020.03.005_bb0175","doi-asserted-by":"crossref","first-page":"75","DOI":"10.2967\/jnumed.116.178889","article-title":"Theranostic perspectives in prostate cancer with the gastrin-releasing peptide receptor antagonist NeoBOMB1: preclinical and first clinical results","volume":"58","author":"Nock","year":"2017","journal-title":"J Nucl Med"},{"key":"10.1016\/j.nucmedbio.2020.03.005_bb0180","doi-asserted-by":"crossref","first-page":"372","DOI":"10.2967\/jnumed.114.147116","article-title":"Dosimetry and first clinical evaluation of the new 18F-radiolabeled bombesin analogue BAY 864367 in patients with prostate cancer","volume":"56","author":"Sah","year":"2015","journal-title":"J Nucl Med"},{"key":"10.1016\/j.nucmedbio.2020.03.005_bb0185","doi-asserted-by":"crossref","first-page":"557","DOI":"10.2967\/jnumed.115.168393","article-title":"Pilot comparison of (6)(8)Ga-RM2 PET and (6)(8)Ga-PSMA-11 PET in patients with biochemically recurrent prostate cancer","volume":"57","author":"Minamimoto","year":"2016","journal-title":"J Nucl Med"},{"key":"10.1016\/j.nucmedbio.2020.03.005_bb0190","doi-asserted-by":"crossref","first-page":"293","DOI":"10.2967\/jnumed.116.176636","article-title":"68Ga\/177Lu-NeoBOMB1, a novel radiolabeled GRPR antagonist for theranostic use in oncology","volume":"58","author":"Dalm","year":"2017","journal-title":"J Nucl Med"},{"key":"10.1016\/j.nucmedbio.2020.03.005_bb0195","first-page":"1152","article-title":"Gastrin-releasing peptide receptors in the human prostate: relation to neoplastic transformation","volume":"59","author":"Markwalder","year":"1999","journal-title":"Cancer Res"},{"key":"10.1016\/j.nucmedbio.2020.03.005_bb0200","doi-asserted-by":"crossref","first-page":"1883","DOI":"10.2967\/jnumed.117.198192","article-title":"Will GRPR compete with PSMA as a target in prostate cancer?","volume":"58","author":"Iagaru","year":"2017","journal-title":"J Nucl Med"},{"key":"10.1016\/j.nucmedbio.2020.03.005_bb0205","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1007\/s00259-013-2527-3","article-title":"Preclinical evaluation of BAY 1075553, a novel (18)F-labelled inhibitor of prostate-specific membrane antigen for PET imaging of prostate cancer","volume":"41","author":"Lesche","year":"2014","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1016\/j.nucmedbio.2020.03.005_bb0210","doi-asserted-by":"crossref","first-page":"6817","DOI":"10.1158\/0008-5472.CAN-11-1646","article-title":"Inhibition of neurotensin receptor 1 selectively sensitizes prostate cancer to ionizing radiation","volume":"71","author":"Valerie","year":"2011","journal-title":"Cancer Res"},{"key":"10.1016\/j.nucmedbio.2020.03.005_bb0215","doi-asserted-by":"crossref","first-page":"3093","DOI":"10.1021\/acs.molpharmaceut.8b00192","article-title":"Development of [(18)F]AlF-NOTA-NT as PET agents of neurotensin receptor-1 positive pancreatic cancer","volume":"15","author":"Wang","year":"2018","journal-title":"Mol Pharm"},{"key":"10.1016\/j.nucmedbio.2020.03.005_bb0220","doi-asserted-by":"crossref","first-page":"4673","DOI":"10.1073\/pnas.91.11.4673","article-title":"Neurotensin is an autocrine trophic factor stimulated by androgen withdrawal in human prostate cancer","volume":"91","author":"Sehgal","year":"1994","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.nucmedbio.2020.03.005_bb0225","doi-asserted-by":"crossref","first-page":"4875","DOI":"10.1038\/s41388-019-0750-5","article-title":"Neurotensin and its receptors mediate neuroendocrine transdifferentiation in prostate cancer","volume":"38","author":"Zhu","year":"2019","journal-title":"Oncogene"},{"key":"10.1016\/j.nucmedbio.2020.03.005_bb0230","doi-asserted-by":"crossref","first-page":"2199","DOI":"10.1007\/s00259-019-04355-y","article-title":"Evaluation of neurotensin receptor 1 as potential biomarker for prostate cancer theranostic use","volume":"46","author":"He","year":"2019","journal-title":"Eur J Nucl Med Mol Imaging"}],"container-title":["Nuclear Medicine and Biology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0969805119306006?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0969805119306006?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,19]],"date-time":"2025-10-19T04:29:11Z","timestamp":1760848151000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0969805119306006"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,5]]},"references-count":46,"alternative-id":["S0969805119306006"],"URL":"https:\/\/doi.org\/10.1016\/j.nucmedbio.2020.03.005","relation":{},"ISSN":["0969-8051"],"issn-type":[{"value":"0969-8051","type":"print"}],"subject":[],"published":{"date-parts":[[2020,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A comparative study of peptide-based imaging agents [68Ga]Ga-PSMA-11, [68Ga]Ga-AMBA, [68Ga]Ga-NODAGA-RGD and [68Ga]Ga-DOTA-NT-20.3 in preclinical prostate tumour models","name":"articletitle","label":"Article Title"},{"value":"Nuclear Medicine and Biology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.nucmedbio.2020.03.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}